Form of Subscription Agreement relating to the initial Series A financing



 Exhibit 10.3 
 SUBSCRIPTION AGREEMENT 
 This SUBSCRIPTION AGREEMENT (this
“Agreement”) is made as of the last date set forth on the signature page hereof between Coronado Biosciences, Inc., a Delaware corporation having its principal place of business at 1700 Seventh Avenue; Suite 2100; Seattle,
Washington 98101 (the “Company”), and the undersigned (the “Subscriber”). 
 W I T N E S S E
T H: 
 WHEREAS, the Company has retained Paramount BioCapital, Inc. (the “Lead Placement Agent”) to
act as its exclusive lead placement agent, on a “reasonable best efforts” basis, in a private offering (the “Offering”) of the Company’s series A preferred stock (the “Series A Stock”), and in
connection therewith has authorized the Lead Placement Agent to engage one or more other firms to assist in finding qualified subscribers for the Series A Stock (such other firms, if any, together with the Lead Placement Agent, the
“Placement Agents”); 
 WHEREAS, the terms of the Offering are summarized in that certain Confidential
Offering Memorandum dated January 20, 2010 (together with all amendments, supplements, exhibits and appendices thereto, the “Memorandum”); 
 WHEREAS, the Company desires to offer and sell, at a price of $8.39 per share (the “Purchase Price Per Share”), a minimum of $1,000,000 of Series A Stock (the “Minimum
Offering”) and a maximum of $30,000,000 of Series A Stock (the “Maximum Amount”) (it being understood that conversion of the Existing Notes other than New Indebtedness (each as defined in the Memorandum) into Series A Stock
does not count toward the Minimum Offering or against the Maximum Amount); and 
 WHEREAS, the Company desires to enter
into this Agreement to issue and sell the Series A Stock and the Subscriber desires to purchase the number of shares of Series A Stock set forth on the signature page hereto on the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the promises and the mutual representations and covenants hereinafter set forth, the parties
hereto do hereby agree as follows: 
  

	I.	SUBSCRIPTION FOR SERIES A STOCK AND REPRESENTATIONS BY SUBSCRIBER 

 1.1 Subject to the terms and conditions hereinafter set forth, the Subscriber hereby irrevocably subscribes for and agrees to purchase from the Company that number of shares of Series A Stock set forth on
the signature page hereto (the “Subscription Amount”) in the form of either (i) immediately available U.S. dollars in the amount of the Subscription Amount by wire transfer or (ii) to the extent provided for by the
Existing Notes (as defined in the Memorandum), the conversion of the aggregate principal amount plus accrued and unpaid interest thereon. Wire transfers shall be delivered to: 

 

					
	Bank:	  	U.S. Bank National Association Corporation	  	
		  	Trust St. Paul MN	  	
	ABA Number:	  	091000022	  	
	Further Credit to Account Name:	  	U.S. Bank N.A.	  	
	Account #:	  	180121167365	  	
	Final Beneficiary Recipient/Subacct:	  	Paramount BioCap & Coronado Biosciences	  	
	SEI/Subacct Number:	  	134617000	  	
	Reference:	  	[Investor Name]	  	


  
 1 









					
	Attention:	  	Stefan Ronchetti	  	
		  	651-495-2148 (phone)	  	
		  	651-495-8087 (fax)	  	

 Upon acceptance by the Placement Agents and the Company of subscriptions equal to at least the Minimum
Offering, the Lead Placement Agent and the Company shall have the right at any time thereafter, prior to the Offering Termination Date (as defined in Section 3.2), to effect an initial closing with respect to the Offering (the “Initial
Closing”). Thereafter, the Placement Agents and the Company shall continue to accept additional subscriptions for, and continue to have closings (together with the Initial Closing, each a “Closing” and the date thereof the
“Closing Date”) with respect to subscriptions for Series A Stock from new or existing investors from time to time and at any time up to the Offering Termination Date. 

The Subscriber understands that the Company’s and the Placement Agents’ respective officers, directors, employees and/or
affiliates may purchase Series A Stock in this Offering, which purchases may be used to satisfy the Minimum Offering. 
 1.2 The
Subscriber recognizes that the purchase of the Series A Stock involves a high degree of risk including, but not limited to, the following: (a) the Company remains a development stage business with limited operating history and requires
substantial funds in addition to the proceeds of the Offering; (b) an investment in the Company is highly speculative, and only investors who can afford the loss of their entire investment should consider investing in the Company and the Series
A Stock; (c) the Subscriber may not be able to liquidate its investment; (d) transferability of the Series A Stock and shares of the Company’s common stock issuable upon conversion of the Series A Stock (sometimes referred to as the
“Securities”) is extremely limited; (e) in the event of a disposition of the Securities, the Subscriber could sustain the loss of its entire investment; and (f) the Company has not paid any dividends on its capital stock
since its inception and, except for the potential payment of the “Special Dividend” set forth in the Company’s Amended and Restated Certificate of Incorporation, provided to the Subscribers (the “Restated
Certificate”), does not anticipate paying any dividends in the foreseeable future. Without limiting the generality of the representations set forth in Section 1.5 below, the Subscriber represents that the Subscriber has carefully
reviewed the section of the Memorandum captioned “Risk Factors.” 
 1.3 The Subscriber represents that the Subscriber
is an “accredited investor” as such term is defined in Rule 501 of Regulation D (“Regulation D”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), as indicated by the
Subscriber’s responses to the questions contained in Article VII hereof, and that the Subscriber is able to bear the economic risk of an investment in the Securities. If the Subscriber is a natural person, the Subscriber has reached the age of
majority in the state or other jurisdiction in which the Subscriber resides, has adequate means of providing for the Subscriber’s current financial needs and contingencies, is able to bear the substantial economic risks of an investment in the
Securities for an indefinite period of time, has no need for liquidity in such investment and, at the present time, could afford a complete loss of such investment. 
 1.4 The Subscriber hereby acknowledges and represents that (a) the Subscriber has sufficient knowledge and experience in business and financial matters, prior investment experience, including
investment in securities that are non-listed, unregistered and/or not traded on a national securities exchange, or the Subscriber has employed the services of a “purchaser representative” (as defined in Rule 501 of Regulation D), attorney
and/or accountant to read all of the documents furnished or made available by the Company both to the Subscriber and to all other prospective investors in the Securities in order to evaluate the merits and risks of such an investment on the
Subscriber’s behalf; (b) the Subscriber recognizes the highly speculative nature of this investment; and (c) the Subscriber is able to bear the economic risk that the Subscriber hereby assumes. 

  
 2 








 1.5 The Subscriber hereby acknowledges receipt and careful review of this Agreement and the
Memorandum (which includes the Risk Factors), including all exhibits thereto (collectively referred to as the “Offering Materials”) and hereby represents that the Subscriber has been furnished by the Company during the course of the
Offering with all information regarding the Company, the terms and conditions of the Offering and any additional information that the Subscriber, its purchaser representative, attorney and/or accountant has requested or desired to know, and has been
afforded the opportunity to ask questions of and receive answers from duly authorized officers or other representatives of the Company concerning the Company and the terms and conditions of the Offering. 

1.6 (a) In making the decision to invest in the Securities, the Subscriber has relied solely upon the information provided by the Company
in the Offering Materials. To the extent necessary, the Subscriber has retained, at its own expense, and relied upon appropriate professional advice regarding the investment, tax and legal merits and consequences of this Agreement and the purchase
of the Securities hereunder. The Subscriber disclaims reliance on any statements made or information provided by any person or entity in the course of Subscriber’s consideration of an investment in the Securities other than the Offering
Materials. The Subscriber acknowledges and agrees that (i) the Company has prepared the Offering Materials and that no other person, including without limitation, any Placement Agent, has supplied any information for inclusion in the Offering
Materials other than information furnished in writing to the Company by the Placement Agents specifically for inclusion in those parts of the Offering Materials relating specifically to the Placement Agents, (ii) the Placement Agents have no
responsibility for the accuracy or completeness of the Offering Materials and (iii) the Subscriber has not relied upon the independent investigation or verification, if any, that may have been undertaken by the Placement Agents. 

(b) The Subscriber represents that (i) the Subscriber was contacted regarding the sale of the Securities by the Company or a
Placement Agent (or an authorized agent or representative of the Company or a Placement Agent) with whom the Subscriber had a prior substantial pre-existing relationship and (ii) no Securities were offered or sold to it by means of any form of
general solicitation or general advertising, and in connection therewith, the Subscriber did not (A) receive or review any advertisement, article, notice or other communication published in a newspaper or magazine or similar media or broadcast
over television or radio, whether closed circuit, or generally available; or (B) attend any seminar meeting or industry investor conference whose attendees were invited by any general solicitation or general advertising. 

1.7 The Subscriber hereby represents that the Subscriber, either by reason of the Subscriber’s business or financial experience or
the business or financial experience of the Subscriber’s professional advisors (who are unaffiliated with and not compensated by the Company or any affiliate or selling agent of the Company, including the Placement Agents, directly or
indirectly), has the capacity to protect the Subscriber’s own interests in connection with the transaction contemplated hereby. 
 1.8 The Subscriber hereby acknowledges that the Offering has not been reviewed by the United States Securities and Exchange Commission (the “SEC”) nor any state regulatory authority since
the Offering is intended to be exempt from the registration requirements of Section 5 of the Securities Act pursuant to Regulation D promulgated thereunder. The Subscriber understands that the Securities have not been registered under the
Securities Act or under any state securities or “blue sky” laws and agrees not to sell, pledge, assign or otherwise transfer or dispose of the Securities unless they are registered under the Securities Act and under any applicable state
securities or “blue sky” laws or unless an exemption from such registration is available. 

  
 3 








 1.9 The Subscriber understands that the Securities have not been registered under the
Securities Act or any state securities laws by reason of a claimed exemption under the provisions of the Securities Act and such state securities laws that depends, in part, upon the Subscriber’s investment intention. The Subscriber hereby
represents that the Subscriber is purchasing the Securities for the Subscriber’s own account for investment and not with a view toward the resale or distribution to others. The Subscriber, if an entity, further represents that it was not formed
for the purpose of purchasing the Securities. 
 1.10 The Subscriber understands that there is no public market for the
Securities and that no market may develop for any of such Securities. The Subscriber understands that even if a public market develops for such Securities, Rule 144 (“Rule 144”) promulgated under the Securities Act requires for
non-affiliates, among other conditions, a one-year holding period prior to the resale (in limited amounts) of securities acquired in a non-public offering without having to satisfy the registration requirements under the Securities Act. The
Subscriber understands and hereby acknowledges that the Company is under no obligation to register any of the Securities under the Securities Act or any state securities or “blue sky” laws other than as set forth in Article V. 

1.11 The Subscriber consents to the placement of a legend on any certificate or other document evidencing the Securities that such
Securities have not been registered under the Securities Act or any state securities or “blue sky” laws and setting forth or referring to the restrictions on transferability and sale thereof contained in this Agreement. The Subscriber is
aware that the Company will make a notation in its appropriate records with respect to the restrictions on the transferability of such Securities. The legend to be placed on each certificate shall be in form substantially similar to the following:

 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”) OR ANY STATE SECURITIES OR “BLUE SKY” LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN
OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.” 

1.12 The Subscriber hereby represents that the address of the Subscriber furnished by Subscriber on the signature page hereof is the
Subscriber’s principal residence if Subscriber is an individual or its principal business address if it is a corporation or other entity. 
 1.13 The Subscriber represents that the Subscriber has full power and authority (corporate, statutory and otherwise) to execute and deliver this Agreement and to purchase the Securities. This Agreement
constitutes the legal, valid and binding obligation of the Subscriber, enforceable against the Subscriber in accordance with its terms. 
 1.14 If the Subscriber is a corporation, partnership, limited liability company, trust, employee benefit plan, individual retirement account, Keogh Plan, or other tax-exempt entity, (a) it is
authorized and qualified to invest in the Company and the person signing this Agreement on behalf of such entity has been duly authorized by such entity to do so and (b) it is duly organized, validly existing and in good standing under the laws
of the jurisdiction of its organization. 
 1.15 The Subscriber acknowledges that if he or she is a Registered Representative of
a Financial Industry Regulatory Authority (“FINRA”) member firm, he or she must give such firm the notice required by FINRA Rule 3050, receipt of which must be acknowledged by such firm in Section 7.3 below. 

  
 4 








 1.16 Subject to the provision below, the Subscriber hereby agrees that in the case of an
initial offering of the Company’s securities to the public pursuant to an effective registration statement under the Securities Act (the “IPO”), the Subscriber will not, without the prior written consent of the Company, offer,
pledge, sell, contract to sell, grant any option for the sale of, or otherwise dispose of, directly or indirectly, the Registrable Securities (as defined in Section 5.1) purchased or acquired by the Subscriber for a period of up to 180 days
from the effective date of the registration statement relating to the IPO (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance
with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation) and that the Subscriber will enter into an agreement with the Company or managing underwriter of the IPO to that effect. 

1.17 (a) The Subscriber agrees not to issue any public statement with respect to the Subscriber’s investment or proposed investment
in the Company or the terms of any agreement or covenant between them and the Company without the Company’s prior written consent, except such disclosures as may be required under applicable law or under any applicable order, rule or
regulation. 
 (b) The Company agrees not to disclose the names, addresses or any other information about the Subscribers,
except as required by law, including without limitation the use of the name (but not the address) of the Subscriber in any registration statement filed pursuant to Article V in which the Subscriber’s shares are included and the disclosure of
such information in any subsequent offering memorandum if the Subscriber beneficially owns five percent (5%) or more of the Company’s voting capital stock. 
 1.18 The Subscriber represents and warrants that it has not engaged, consented to or authorized any broker, finder or intermediary to act on its behalf, directly or indirectly, as a broker, finder or
intermediary in connection with the transactions contemplated by this Agreement. The Subscriber hereby agrees to indemnify and hold harmless the Company from and against all fees, commissions or other payments owing to any such person or firm acting
on behalf of such Subscriber hereunder. 
 1.19 The Subscriber agrees to hold the Company and its directors, officers,
employees, affiliates, controlling persons and agents (including any Placement Agent and its officers, directors, employees, counsel, controlling persons and agents) and their respective heirs, representatives, successors and assigns harmless and to
indemnify them against all liabilities, costs and expenses incurred by them as a result of (a) any sale or distribution of the Securities by the Subscriber in violation of the Securities Act or any applicable state or foreign securities or
“blue sky” laws; or (b) any false representation or warranty or any breach or failure by the Subscriber to comply with any covenant made by the Subscriber in this Agreement (including the Confidential Investor Questionnaire contained
in Article VII herein) or any other document furnished by the Subscriber to any of the foregoing in connection with this transaction; provided, however, that in no event shall any indemnity under this Subsection 1.19 exceed the Subscription Amount
subscribed for by the Subscriber pursuant to this Agreement, except in the case of willful fraud by the Subscriber. 
 1.20 The
Subscriber understands, acknowledges and agrees with the Company that this subscription may be rejected, in whole or in part, by the Company, in the sole and absolute discretion of the Company, at any time before the Closing Date notwithstanding
prior receipt by the Subscriber of notice of acceptance of the Subscriber’s subscription. 

  
 5 








 1.21 The Subscriber acknowledges that the information contained in the Offering Materials or
otherwise made available to the Subscriber is confidential and non-public and agrees that all such information shall be kept in confidence by the Subscriber and neither used by the Subscriber for the Subscriber’s personal benefit (other than in
connection with this subscription) nor disclosed to any third party for any reason, notwithstanding that a Subscriber’s subscription may not be accepted by the Company; provided, however, that (a) the Subscriber may disclose such
information to its attorneys and advisors who may have a need for such information in connection with providing advice to the Subscriber with respect to its investment in the Company, so long as such affiliates and advisors have an obligation of
confidentiality, and (b) this obligation shall not apply to any such information that (i) is part of the public knowledge or literature and readily accessible at the date hereof, (ii) becomes part of the public knowledge or literature
and readily accessible by publication (except as a result of a breach of this provision), or (iii) is received from third parties without an obligation of confidentiality (except third parties who disclose such information in violation of any
confidentiality agreements or obligations, including, without limitation, any subscription or other similar agreement entered into with the Company). 
 1.22 The Subscriber represents that no authorization, approval, consent or license of any person is required to be obtained for the purchase of the Securities by the Subscriber, other than as have been
obtained and are in full force and effect. 
 1.23 The Subscriber represents that the representations, warranties and agreements
of the Subscriber contained herein and in any other writing delivered in connection with the transactions contemplated hereby shall be true and correct in all respects on the date hereof and as of the Closing Date on which the Subscriber purchases
Series A Stock as if made on and as of such date and shall survive the execution and delivery of this Agreement and the purchase of the Series A Stock. The Subscriber agrees that the Company and the Placement Agents shall be entitled to rely on the
representations, warranties and agreements of the Subscriber contained herein. 
 1.24 The Subscriber understands, acknowledges
and agrees with the Company that, except as otherwise set forth herein, the subscription hereunder is irrevocable by the Subscriber, that, except as required by law, the Subscriber is not entitled to cancel, terminate or revoke this Agreement or any
agreements of the Subscriber hereunder and that this Agreement and such other agreements shall survive the death or disability of the Subscriber and shall be binding upon and inure to the benefit of the parties and their heirs, executors,
administrators, successors, legal representatives and permitted assigns. If the Subscriber is more than one person, the obligations of the Subscriber hereunder shall be joint and several and the agreements, representations, warranties and
acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and his/her heirs, executors, administrators, successors, legal representatives and permitted assigns. 

1.25 The Subscriber understands, acknowledges and agrees with the Company that the Offering is intended to be exempt from registration
under the Securities Act by virtue of the provisions of Regulation D thereunder, which is in part dependent upon the truth, completeness and accuracy of the representations and covenants made by the Subscriber in this Agreement. 

1.26 The Subscriber understands, acknowledges, covenants and agrees that until the earlier to occur of the “Time-based Automatic
Conversion Date” or the “Milestone Conversion Date” (each as defined in the Restated Charter) neither the Subscriber nor any of its affiliates nor any entity managed or controlled by the Subscriber will ever (i) enter into or
execute or cause any person or entity to enter into or execute any “short sale” (as such term is defined in Rule 200 of Regulation SHO or any successor regulation promulgated by the SEC under the Exchange Act) of Series A Stock, Common
Stock or any other equity securities of the Company or (ii) engage, through related parties or otherwise, in any 

  
 6 








 
derivative or hedging transaction directly related to the Company’s equity securities (including, without limitation, the purchase of any option or contract to sell). Further, Subscriber
agrees that, upon the reasonable request of the Company, Subscriber will, and it will use its best efforts to cause its affiliates or any entity managed or controlled by the Subscriber to, verify in writing to the Company that it has not engaged in
any such short sale, derivative hedging transaction directly related to such securities. 
 1.27 (a) Any Subscriber subject to
jurisdiction in the European Economic Area (“EEA”) either (i) is a qualified investor for the purposes of Directive 2003/71/EC of the European Parliament and the Council (a “Qualified Investor”); that is, a
person falling within Article 2.1(e)(i), (ii) or (iii) of such directive or a person authorized by any such jurisdiction to be considered as a qualified investor for the purposes of such directive, or (ii) it has notified the Lead
Placement Agent in writing that it is not a Qualified Investor; 
 (b) Any EEA Subscriber entering into this Agreement and
acquiring Securities is either (i) acting on its own account and not for the account of or otherwise on behalf any other person or persons or (ii) if a Qualified Investor in the United Kingdom, it is acting as an agent in the circumstances
contemplated in section 86(2) of the United Kingdom Financial Services and Markets Act 2000; 
 (c) Any Subscriber, if in the
United Kingdom, is (a) a person falling within Article 19(5) of the United Kingdom Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“FPO”) or (b) a person falling within Article 49(2)(a) to
(d) of the FPO; 
 (d) Each Subscriber acknowledges that no Placement Agent nor any person acting on its behalf is making
any recommendations to it or advising it regarding the suitability or merits of purchasing Securities or any transaction it may enter into in connection with the offering of the Securities. 

 

	II.	REPRESENTATIONS BY AND COVENANTS OF THE COMPANY 

 The Company hereby represents and warrants to the Subscriber that: 
 2.1
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has full corporate power and authority to conduct its business as
currently conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the property owned or leased by it or the nature of the business conducted by it makes such
qualification necessary, except to the extent that the failure to be so qualified or in good standing would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, operations, conditions
(financial or otherwise), properties, assets or results of operations of the Company (a “Material Adverse Effect”). 
 2.2 Capitalization and Voting Rights. The authorized, issued and outstanding shares of the capital stock of the Company is as set forth in the Memorandum and all issued and outstanding shares of
the Company are validly issued, fully paid and nonassessable. Except as set forth in the Memorandum, there are no outstanding options, warrants, agreements, convertible securities, preemptive rights or other rights to subscribe for or to purchase
any shares of capital stock of the Company. Except as set forth in the Offering Materials and as otherwise required by law, there are no restrictions upon the voting or transfer of any of the shares of capital stock of the Company pursuant to the
Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), By-Laws or other governing documents or any agreement or other instruments to which the Company is a party or by which the Company is
bound. 

  
 7 








 2.3 Authorization; Enforceability. The Company has all corporate right, power and
authority to enter into this Agreement and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the (i) authorization, execution, delivery and
performance of this Agreement by the Company; and (ii) authorization, sale, issuance and delivery of the Series A Stock contemplated hereby and the performance of the Company’s obligations hereunder has been taken. This Agreement has been
duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency
and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies, and to limitations of public policy. The Series A Stock, when issued and fully paid for in accordance with the terms of this
Agreement, will be validly issued, fully paid and nonassessable. The issuance and sale of the Securities contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person which have not been waived in
connection with this Offering. 
 2.4 No Conflict; Governmental Consents. 

(a) Except as would not reasonably be expected to have a Material Adverse Effect or have been waived, the execution and delivery by the
Company of this Agreement and the consummation of the transactions contemplated hereby will not result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court or governmental authority to or
by which the Company is bound, or of any provision of the Certificate of Incorporation or By-Laws of the Company, and will not conflict with, or result in a breach or violation of, any of the terms or provisions of, or constitute (with due notice or
lapse of time or both) a default under, any lease, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Company is a party or by which it is bound or to which any of its properties or assets is
subject, nor result in the creation or imposition of any lien upon any of the properties or assets of the Company. 
 (b) No
consent, approval, authorization or other order of any governmental authority or other third party is required to be obtained by the Company in connection with the authorization, execution and delivery of this Agreement or with the authorization,
issue and sale of the Securities, except as have been obtained or such filings as may be required to be made with the SEC and with any state or foreign blue sky or securities regulatory authority relating to an exemption from registration
thereunder. 
 2.5 Licenses. Except as would not reasonably be expected to have a Material Adverse Effect, the Company
has sufficient licenses, permits and other governmental authorizations currently required for the conduct of its business or ownership of properties and is in all material respects complying therewith. 

2.6 Litigation. Except as set forth in the Memorandum, the Company knows of no pending or threatened legal or governmental
proceedings against the Company which (i) adversely questions the validity of this Agreement or any agreements related to the transactions contemplated hereby or the right of the Company to enter into any of such agreements, or to consummate
the transactions contemplated hereby or thereby or (ii) could, if there were an unfavorable decision, have a Material Adverse Effect. There is no action, suit, proceeding or investigation by the Company currently pending in any court or before
any arbitrator or that the Company intends to initiate. 

  
 8 








 2.7 Investment Company. The Company is not an “investment company” within
the meaning of such term under the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder. 
 2.8 Lead Placement Agent. The Company has engaged, consented to and authorized the Lead Placement Agent to act as agents of the Company in connection with the transactions contemplated by this
Agreement, in accordance with the Engagement Agreement (as defined in the Memorandum). The Company will issue the Placement Agents warrants to purchase Series A Stock and will pay the Placement Agents cash commissions as described in the Memorandum.
The Company will also reimburse the Lead Placement Agent’s reasonable out-of-pocket expenses incurred in connection with the Offering up to $25,000, and the Company agrees to indemnify and hold harmless the Subscribers from and against all
fees, commissions or other payments owing by the Company to the Placement Agents or any other person or firm acting on behalf of the Company hereunder. 
 2.9 Financial Statements. The financial statements of the Company included in Exhibit B to the Memorandum (the “Financial Statements”) fairly present in all material respects the
financial condition and results of operations of the Company at the dates and for the periods indicated and have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistently
applied throughout the periods covered thereby, except as may be otherwise specified in such Financial Statements or the notes thereto, and except that unaudited financial statements do not contain all footnotes and do not contain the cash flow
statement required by GAAP, and fairly present in all material respects the financial condition of the Company as of the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal year-end audit adjustments. Since the date of the most recent balance sheet included as part of the Financial Statements, there has not been to the Company’s knowledge: (i) any change in the assets, liabilities,
financial condition or operations of the Company from that reflected in the Financial Statements, other than changes in the ordinary course of business, none of which individually or in the aggregate would reasonably be expected to have a Material
Adverse Effect; or (ii) any other event or condition of any character that, either individually or cumulatively, would reasonably be expected to have a Material Adverse Effect, except for the expenses incurred in connection with the
transactions contemplated by this Agreement. 
 2.10 Title to Properties and Assets; Liens, Etc. The Company has good and
marketable title to its properties and assets, including the properties and assets reflected in the most recent balance sheet included in the Financial Statements, and good title to its leasehold estates, in each case subject to no mortgage, pledge,
lien, lease, encumbrance or charge, other than (a) those resulting from taxes which have not yet become delinquent; (b) liens and encumbrances which do not materially detract from the value of the property subject thereto or materially
impair the operations of the Company; (c) those that have otherwise arisen in the ordinary course of business; and (d) those that would not reasonably be expected to have a Material Adverse Effect. The Company is in compliance with all
material terms of each lease to which it is a party or is otherwise bound. 
 2.11 Patents and Trademarks. Except as
would not reasonably be expected to have a Material Adverse Effect or as disclosed in the Memorandum, to the Company’s knowledge, (i) the Company owns or possesses adequate licenses or other rights to use all patents, patent applications,
trademarks, trademark applications, service marks, service mark applications, trade names, copyrights, manufacturing processes, formulae, trade secrets, licenses, customer lists and know how (collectively, “Intellectual Property”),
(ii) the Company has not received any communications alleging that the Company has violated or, by conducting its business as conducted, would violate any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or
other proprietary rights or processes of any other person or entity, nor is the Company aware of any basis therefor and (iii) no claim 

  
 9 








 
is pending or, to the Company’s knowledge after due inquiry, threatened to the effect that any Intellectual Property owned or licensed by the Company, or which the Company otherwise has the
right to use, is invalid or unenforceable by the Company. 
 2.12 Obligations to Related Parties. Except as disclosed in
the Memorandum or as would not reasonably be expected to have a Material Adverse Effect, there are no obligations of the Company to officers, directors, stockholders, or employees of the Company other than (a) for payment of salary or other
compensation for services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company, (c) standard indemnification provisions in the certificate of incorporation and by-laws, and (d) for other standard
employee benefits made generally available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company). Except as may be disclosed in the Financial Statements, the
Company is not a guarantor or indemnitor of any indebtedness of any other person, firm or corporation. 
 2.13 Employee
Relations; Employee Benefit Plans. The Company is not a party to any collective bargaining agreement or a union contract. The Company believes that its relations with its employees are good. No executive officer (as defined in Rule 501(f) of the
Securities Act) of the Company has notified the Company that such officer intends to leave the Company or otherwise terminate such officer’s employment with the Company. The Company is in compliance with all federal, state, local and foreign
laws and regulations respecting employment and employment practices, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to
result in a Material Adverse Effect. Except as disclosed in the Memorandum, the Company does not maintain any compensation or benefit plan, agreement, arrangement or commitment (including, but not limited to, “employee benefit plans”, as
defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)) for any present or former employees, officers or directors of the Company or with respect to which the Company has liability
or makes or has an obligation to make contributions, other than any such plans, agreements, arrangements or commitments made generally available to the Company’s employees. 

2.14 Environmental Laws. To its knowledge, the Company (i) is in compliance with any and all Environmental Laws (as
hereinafter defined), (ii) has received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct its business and (iii) is in compliance with all terms and conditions of any such permit,
license or approval where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. The term “Environmental
Laws” means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata),
including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the
environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions,
judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder. 
 2.15 Tax Status. To the best of the Company’s knowledge, the Company (i) has made or filed all federal and state income and all other tax returns, reports and declarations required by any
jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in
good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the Company knows of no basis for any such claim. 

  
 10 









 2.16 Absence of Certain Changes. Since the date of the Memorandum, there has been no
change in the business, operations, conditions (financial or otherwise), prospects, assets or results of operations of the Company or any of its Subsidiaries that could reasonably be expected to have a Material Adverse Effect. 

2.17 Disclosure. The information set forth in the Offering Materials as of the date hereof contains no untrue statement of a
material fact nor omits to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading. 

 

	III.	TERMS OF SUBSCRIPTION 


3.1 The minimum purchase that may be made by any prospective investor shall be $50,000. Subscriptions for investment below the minimum
investment may be accepted at the discretion of the Lead Placement Agent and the Company. The Company reserves the right to reject any subscription made hereby, in whole or in part, in its sole discretion. The Company’s agreement with each
Subscriber is a separate agreement and the sale of the Securities to each Subscriber is a separate sale. 
 3.2 Pending the sale
of the Series A Stock, all funds paid hereunder shall be deposited by the Company in escrow with U.S. Bank N.A., having a branch at 100 Wall Street, Suite 1600, New York, New York 10005 (“Escrow Agent”). This Offering will terminate
on the earlier of (i) the Company’s acceptance of subscriptions for the Maximum Amount, or (ii) March 31, 2010, unless terminated at an earlier time or extended by the mutual agreement of the Lead Placement Agent and the Company
without notice to prospective investors for up to an additional sixty (60) days (the “Offering Termination Date”). The Company reserves the right to withdraw or cancel this Offering and to accept or reject any subscription in
whole or in part, in its sole discretion. The Subscriber hereby authorizes and directs the Company and the Lead Placement Agent to direct the Escrow Agent to return any funds for unaccepted subscriptions to the same account from which the funds were
drawn, without interest. 
 3.3 At any time after the Company has received subscriptions and related funds for the Minimum
Offering, but prior to the Offering Termination Date, the Company may conduct a Closing and may conduct subsequent Closings on an interim basis until the Maximum Amount has been obtained or until the Offering Termination Date. Each Closing shall
occur at the offices of Cooley Godward Kronish LLP, 4401 Eastgate Mall, San Diego, CA 92121. 
 3.4 The certificate for Series A
Stock purchased by the Subscriber pursuant to this Agreement will be prepared for delivery to the Subscriber promptly following the Closing at which such purchase takes place. The Subscriber hereby authorizes and directs the Company to deliver the
certificate for Series A Stock purchased by the Subscriber pursuant to this Agreement to the residential or business address indicated on the signature page hereto. 
  

	IV.	CONDITIONS TO OBLIGATIONS OF THE PARTIES 

 4.1 In addition to the Company’s right to reject, in whole or in part, any subscription at any time before the Closing Date, the Company’s obligation to issue the Series A Stock at each Closing
to the applicable Subscriber is subject to the fulfillment on or prior to such Closing of the following conditions, which conditions may be waived at the option of the Company to the extent permitted by law: 

(a) The representations and warranties made by each Subscriber in Article I hereof shall be true and correct in all material respects.


  
 11 









 (b) All covenants, agreements and conditions contained in this Agreement to be performed by
such Subscriber on or prior to the date of such Closing shall have been performed or complied with in all material respects. 

(c) There shall not then be in effect any legal or other order enjoining or restraining the transactions contemplated by this Agreement.

 (d) The Restated Certificate, in substantially the form provided to the Subscribers, shall have been filed with the
Secretary of State of the State of Delaware and shall be in full force and effect as of the Initial Closing. 
 (e) There shall
not be in effect any law, rule or regulation prohibiting or restricting such sale or requiring any consent or approval of any person, which shall not have been obtained, to issue the Series A Stock (except as otherwise provided in this Agreement).

 4.2 The Subscriber’s obligation to purchase the Series A Stock at the Closing at which such purchase is to be
consummated is subject to the fulfillment on or prior to such Closing of the following conditions, which conditions may be waived at the option of each Subscriber to the extent permitted by law: 

(a) The representations and warranties made by the Company in Article II hereof shall be true and correct in all material respects.

 (b) The Minimum Amount (which shall not include conversion of the Existing Notes, other than New Indebtedness, into Series A
Stock) shall have been subscribed for. 
 (c) All covenants, agreements and conditions contained in this Agreement to be
performed by the Company on or prior to the date of such Closing shall have been performed or complied with in all material respects. 
 (d) There shall not then be in effect any legal or other order enjoining or restraining the transactions contemplated by this Agreement. 

(e) The Restated Certificate, in substantially the form provided to the Subscribers, shall have been filed with the Secretary of State
of the State of Delaware and shall be in full force and effect as of the Initial Closing. 
 (f) There shall not be in effect
any law, rule or regulation prohibiting or restricting such sale or requiring any consent or approval of any person, which shall not have been obtained, to issue the Series A Stock (except as otherwise provided in this Agreement). 

(g) The Lead Placement Agent shall have received an opinion of counsel to the Company addressed to the Subscribers (which the Lead
Placement Agent and Paramount BioCapital, Inc. may be permitted to rely on as if it were addressed to it) containing certain customary opinions, which opinion will be subject to standard qualifications and assumptions. 

(h) The Lead Placement Agent shall have received an Officer’s Certificate addressed to the Subscribers, signed by the authorized
officer of the Company and dated as of the 

  
 12 









 
Closing. The certificate shall state, among other things, that the representations and warranties contained herein and in the Offering Materials are true and accurate in all material respects at
such Closing Date with the same effect as though expressly made at such Closing Date and the Lead Placement Agent shall be entitled to rely on such representations of the Company in the Offering Materials as if they were made directly to it.

  

	V.	REGISTRATION RIGHTS 

 5.1
Definitions. As used in this Agreement, the following terms shall have the following meanings. 
 (a) The term
“Holder” shall mean any holder of Registrable Securities. 
 (b) The terms “register”,
“registered” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or order of
effectiveness of such registration statement or document. 
 (c) The term “Registrable Securities” shall mean
(i) the shares of common stock issuable upon the conversion of the Series A Stock sold in the Offering (or any successor security); and (ii) any shares of equity securities issuable (or issuable upon the conversion or exercise of any
warrant, right or other security that is issued) pursuant to a dividend or other distribution with respect to or in replacement of any Securities; provided, however, that securities shall only be treated as Registrable Securities if and only for so
long as they (A) have not been disposed of pursuant to a registration statement declared effective by the SEC; (B) have not been sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act
so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale; (C) are held by a Holder or a permitted transferee of a Holder pursuant to Section 5.11; or (D) may not be
disposed of under Rule 144 under the Securities Act without restriction. 
 (d) The term “Trading Event” means
the first date on which the Company’s Common Stock trades on a national securities exchange or an Over-the-Counter Bulletin Board. 
 5.2 Piggyback Registration. 
 (a) The Company agrees that if, at any time,
and from time to time, after the earlier to occur of (i) an IPO and (ii) a Trading Event, the Board of Directors of the Company (the “Board”) shall authorize the filing of a registration statement under the Securities Act
(other than the filing of a registration statement pursuant to the IPO or a registration statement on Form S-8, Form S-4 or any other form that does not include substantially the same information as would be required in a form for the general
registration of securities) in connection with the proposed offer of any of its securities by it or any of its stockholders, the Company shall: (A) promptly notify each Holder that such registration statement will be filed and that the
Registrable Securities then held by such Holder will be included in such registration statement at such Holder’s request; (B) subject to Section 5.7, cause such registration statement to cover all of such Registrable Securities issued
to such Holder for which such Holder requests inclusion; (C) use reasonable best efforts to cause such registration statement to become effective as soon as practicable; and (D) take all other reasonable action necessary under any Federal
or state law or regulation of any governmental authority to permit all such Registrable Securities that have been issued to such Holder to be sold or otherwise disposed of, and will maintain such compliance with each such Federal and state law and
regulation of any governmental authority for the period necessary for such Holder to promptly effect the proposed sale or other disposition. 

  
 13 









 (b) Notwithstanding any other provision of this Section 5.2, the Company may at any
time, abandon or delay any registration commenced by the Company. In the event of such an abandonment by the Company, the Company shall not be required to continue registration of shares requested by the Holder for inclusion and the Holder shall
retain the right to request inclusion of shares as set forth above. 
 5.3 Demand Registration. 

(a) Registration on Request. 
 (i) The Company agrees that, at any time, and from time to time, but at least 180 days after the earlier to occur of (i) an IPO and (ii) a Trading Event, Holders of a majority of the Registrable
Securities may make a written request that the Company effect the registration under the Securities Act of outstanding Registrable Securities; provided that such requested registration would cover at least 51% of the Registrable Securities
owned by all the Holders at such time; and provided, further, that the Holders shall be entitled to no more than one such demand registration. 
 (ii) The Company further agrees that if, at any time, and from time to time, after the Company has qualified for the use of Form S-3 or any successor form, one or more of the Holders desire to effect the
registration under the Securities Act on Form S-3 or any successor form (“Short-Form Registration”) of outstanding Registrable Securities, such Holder(s) may make a written request that the Company effect a Short-Form Registration;
provided that the aggregate price to the public of the shares as to which such registration is requested (based on the then current market price and before deducting underwriting discounts and commissions) would equal or exceed $5,000,000. It
is understood and agreed that the Holders may make good faith requests for Short-Form Registrations on an unlimited number of occasions; provided further, that the Company shall not be required to effect more than one Short Form Registration
in any 12-month period. 
 (iii) Each request made by one or more of the Holders pursuant to subsection (i) or
(ii) above (the “Initiating Holders”) will specify the number of shares of Registrable Securities proposed to be sold and will also specify the intended method of disposition thereof. Following receipt of any such request, the
Company shall promptly notify all Holders other than the Initiating Holders of receipt of such request and the Company shall use best efforts to file, within 60 days of such request, a registration statement under the Securities Act with respect to
the Registrable Securities that the Company has been so requested to register in the request by the Initiating Holders (and in all notices received by the Company from such other Holders within 30 days after the giving of such notice by the
Company), to the extent necessary to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the Registrable Securities to be registered. If such method of disposition shall be an underwritten public offering, the
Holders of a majority of the shares of Registrable Securities to be sold in such offering may designate the managing underwriter of such offering, subject to the approval of the Company, which approval shall not be unreasonably withheld or delayed.
The Holders will be permitted to withdraw Registrable Securities from a registration at any time prior to the effective date of such registration; provided the remaining number of shares of Registrable Securities subject to a requested
registration is not less than the minimum amount required pursuant to this Section 5.3. 
 (b) Limitations on Demand
Registration. Notwithstanding Section 5.3(a), the Company shall not be obligated to file a registration statement relating to a registration request pursuant to this Section 5.3 at any time during the 180-day period immediately
following the effective date of any registration statement filed by the Company (other than on Form S-8 or S-4 or any other form that does not include substantially the same information as would be required in a form for the general registration


  
 14 









 
of securities); and if the Board determines, in its good faith judgment, that the Company (i) should not file any registration statement otherwise required to be filed pursuant to
Section 5.3 or (ii) should withdraw any such previously filed registration statement because the Board determines, in its good faith judgment, that the Company is in the possession of material nonpublic information required to be disclosed
in such registration statement or an amendment or supplement thereto, the disclosure of which in such registration statement would be materially disadvantageous to the Company (a “Disadvantageous Condition”), the Company shall be
entitled to postpone for the shortest reasonable period of time (but not exceeding 90 days from the date of the determination), the filing of such registration statement or, if such registration statement has already been filed, may suspend or
withdraw such registration statement and shall promptly give the Holders written notice of such determination and an approximation of the anticipated delay. Upon the receipt of any such notice, such Holders shall forthwith discontinue use of the
prospectus contained in such registration statement and, if so directed by the Company, shall deliver to the Company all copies of the prospectus then covering such Registrable Securities current at the time of receipt of such notice (or, if no
registration statement has yet been filed, all drafts of the prospectus covering such Registrable Securities). If any Disadvantageous Condition shall cease to exist, the Company shall promptly notify the Holders to such effect. If any registration
statement shall have been withdrawn, the Company shall, at such time as it is possible or, if earlier, at the end of the 90-day period following such withdrawal, file a new registration statement covering the Registrable Securities that were covered
by such withdrawn registration statement. The Company’s right to delay a request for registration or to withdraw a registration statement pursuant to this Section 5.3 may not be exercised more than once in any one-year period. 

5.4 Registration Procedures. Whenever required under this Article V to include Registrable Securities in a Company registration
statement, the Company shall, as expeditiously as reasonably possible: 
 (a) Use reasonable best efforts to (i) cause
such registration statement to become effective, and (ii) cause such registration statement to remain effective in accordance with Section 5.12 hereof. The Company will also use its reasonable best efforts to, during the period that such
registration statement is required to be maintained hereunder, file such post-effective amendments and supplements thereto as may be required by the Securities Act and the rules and regulations thereunder or otherwise to ensure that the registration
statement does not contain any untrue statement of material fact or omit to state a fact required to be stated therein or necessary to make the statements contained therein, in light of the circumstances under which they are made, not misleading;
provided, however, that if applicable rules under the Securities Act governing the obligation to file a post-effective amendment permits, in lieu of filing a post-effective amendment that (i) includes any prospectus required by
Section 10(a)(3) of the Securities Act or (ii) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the Company may incorporate by reference information required
to be included in (i) or (ii) above in the preceding sentence to the extent such information is contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement. In the event that
the Company becomes qualified for the use of Form S-3 or any successor form at a time when any registration statement on any other Form which includes Registrable Securities is required to be maintained hereunder, the Company shall, upon the request
of any Selling Holder, subject to Section 5.5, (i) as expeditiously as reasonably possible, use reasonable best efforts to cause a Short-Form Registration covering such Registrable Securities to become effective and (ii) comply with
each of the other requirements of this Section 5.4 which may be applicable thereto. Upon the effectiveness of such Short-Form Registration, the Company shall be relieved of its obligations hereunder to keep in effect the registration statement
which initially covered the Registrable Securities included in such Short-Form Registration. 

  
 15 









 (b) Prepare and file with the SEC such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement.

 (c) Furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus as amended or
supplemented from time to time, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d) Use reasonable best efforts to register and qualify the securities covered by such registration statement under the state securities
laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process in any such states, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering.
Each selling Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 
 (f) Notify each Holder of Registrable Securities covered by such registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, (i) when
the registration statement or any post-effective amendment and supplement thereto has become effective; (ii) of the issuance by the SEC of any stop order or the initiation of proceedings for that purpose (in which event the Company shall make
every effort to obtain the withdrawal of any order suspending effectiveness of the registration statement at the earliest possible time or prevent the entry thereof); (iii) of the receipt by the Company of any notification with respect to the
suspension of the qualification of the Registrable Securities for sale in any jurisdiction or the initiation of any proceeding for such purpose; and (iv) of the happening of any event as a result of which the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances
then existing (and each Holder agrees to suspend any trading under the Registration Statement until such condition is abated). 

(g) Cause all such Registrable Securities registered hereunder to be listed on each securities exchange or quotation service on which
similar securities issued by the Company are then listed or quoted or, if no such similar securities are listed or quoted on a securities exchange or quotation service, apply for qualification and use reasonable best efforts to qualify such
Registrable Securities for inclusion on a national securities exchange or the Over-the-Counter Bulletin Board. 
 (h) Provide a
transfer agent and registrar for all Registrable Securities registered hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

(i) Cooperate with the selling Holders and the managing underwriters, if any, to facilitate the timely preparation and delivery of
certificates representing the Registrable Securities to be sold, which certificates will not bear any restrictive legends; and enable such Registrable Securities to be in such denominations and registered in such names as the managing underwriters,
if any, shall request at least two business days prior to any sale of the Registrable Securities to the underwriters. 

  
 16 









 5.5 Furnish Information. It shall be a condition precedent to the obligation of the
Company to take any action pursuant to this Article V with respect to the Registrable Securities of any Holder that such Holder shall furnish to the Company such information regarding the Holder, the Registrable Securities held by the Holder, and
the intended method of disposition of such securities as shall be reasonably required by the Company to effect the registration of such Holder’s Registrable Securities. 
 5.6 Registration Expenses. The Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to registrations
pursuant to Sections 5.2 or 5.3 for each Holder, including (without limitation) all registration, filing, and qualification fees, printers and accounting fees relating or apportionable thereto (“Registration Expenses”), but
excluding underwriting discounts and commissions relating to Registrable Securities and excluding any professional fees or costs of accounting, financial or legal advisors to any of the Holders. 

5.7 Underwriting Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital
stock, the Company shall not be required under Section 5.2 to include any of the Holders’ Registrable Securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters
selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of
securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success
of the offering (the securities so included to be apportioned pro rata among the selling Holders according to the total amount of securities entitled to be included therein owned by each selling Holder or in such other proportions as shall mutually
be agreed to by such selling Holders, subject to giving precedence to holders of registration rights senior in time of grant to the Holders). For purposes of the preceding parenthetical concerning apportionment, for any selling Holder who is a
holder of Registrable Securities and is a partnership or corporation, the partners, retired partners and stockholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any
of the foregoing persons shall be deemed to be a single “selling Holder”, and any pro-rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by
all entities and individuals included in such “selling Holder”, as defined in this sentence. 
 5.8 Delay of
Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this
Article V. 
 5.9 Indemnification. In the event that any Registrable Securities are included in a registration statement
under this Article V: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any
underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint
or several) to which they may become subject under the Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material 

  
 17 









 
fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or
alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, or
any rule or regulation promulgated under the Securities Act, or the Exchange Act, and the Company will pay to each such Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 5.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, or action to the
extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person
or a violation of any provision of this Agreement by a Holder. 
 (b) To the extent permitted by law, each Selling Holder will
indemnify and hold harmless the Company, each of its directors, each of its officers, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration
statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, or the Exchange
Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in
conformity with written information furnished by such Holder expressly for use in connection with such registration or a violation of any provision of this Agreement by a Holder; and each such Holder will pay, as incurred, any legal or other
expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 5.9(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the
indemnity agreement contained in this Section 5.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be
unreasonably withheld; provided, further, that, in no event shall any indemnity under this Section 5.9(b) exceed the greater of the cash value of the (i) gross proceeds from the offering received by such Holder or
(ii) such Holder’s investment pursuant to this Agreement as set forth on the signature page attached hereto. 
 (c)
Promptly after receipt by an indemnified party under this Section 5.9 of notice of the commencement of any action (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any
indemnifying party under this Section 5.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires,
jointly with any other indemnifying party similarly notified, to assume the defense thereof with counsel selected by the indemnifying party and approved by the indemnified party (whose approval shall not be unreasonably withheld); provided, however,
that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability
to the indemnified party under this Section 5.9, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 5.9.


  
 18 









 (d) If the indemnification provided for in this Section 5.9 is held by a court of
competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall
contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and
of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the alleged omission to state a material fact relates to information supplied by the indemnifying
party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public
offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 (f) The
obligations of the Company and Holders under this Section 5.9 shall survive the completion of any offering of Registrable Securities in a registration statement under this Article V, and otherwise. 

5.10 Reports Under Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144 and
any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 

(a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after 90 days after
the effective date of the IPO or Trading Event by the Company; 
 (b) file with the SEC in a timely manner all reports and
other documents required of the Company under the Securities Act and the Exchange Act; and 
 (c) furnish to any Holder, so
long as the Holder owns any Registrable Securities, forthwith upon request (i) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (ii) such other
information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 

5.11 Permitted Transferees. The rights to cause the Company to register Registrable Securities granted to the Holders by the
Company under this Article V may be assigned in full by a Holder in connection with a transfer by such Holder of its Registrable Securities if: (a) such transferee agrees in writing to comply with the terms and provisions of this Agreement;
(b) such transfer is otherwise in compliance with this Agreement; (c) such transfer is otherwise effected in accordance with applicable securities laws; and (d) such Holder transfers at least 51% of its shares of Registrable
Securities to the transferee. Except as specifically permitted by this Section 5.11, the rights of a Holder with respect to Registrable Securities as set out herein shall not be transferable to any other Person, and any attempted transfer of
such registration rights shall by void. 

  
 19 









 5.12 Termination of Registration Rights. The right of any Holder to request or demand
inclusion in any registration pursuant to Section 5.2 and Section 5.3 shall terminate if all Registrable Securities held by such Holder may immediately be sold under Rule 144 without restriction. 

 

	VI.	MISCELLANEOUS 

 6.1 Any
notice or other communication given hereunder shall be deemed sufficient if in writing and sent by registered or certified mail, return receipt requested, or delivered by hand against written receipt therefor, addressed as follows: 

if to the Company, to it at: 
 Coronado Biosciences, Inc. 
 1700 Seventh Avenue 

Suite 2100 

Seattle, Washington 98101 
 Attn: President 
 With a copy to: 

Cooley Godward Kronish LLP 
 4401 Eastgate Mall 
 San Diego, CA 92121 

Facsimile: 858-550-6420 
 Attn: Jason Kent, Esq. 
 if to the Subscriber, to the Subscriber’s address
indicated on the signature page of this Agreement. 
 Notices shall be deemed to have been given or delivered on the date of mailing, except
notices of change of address, which shall be deemed to have been given or delivered when received. 
 6.2 Except as otherwise
expressly provided herein, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified
period of time or indefinitely) with the written consent of the Company and subscribers holding at least a majority of the then outstanding Series A Stock issued in the Offering. Any amendment or waiver effected in accordance with this
Section 6.2 shall be binding upon the Subscriber and the Company (even if the Subscriber does not consent to such amendment or waiver), and upon the effectuation of each such amendment or waiver, the Company shall promptly give written notice
thereof to the Subscriber if the Subscriber has not previously consented thereto in writing. 
 6.3 Subject to the provisions of
Section 5.11, this Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs, legal representatives, successors and assigns. This Agreement sets forth the entire agreement and understanding
between the parties as to the subject matter hereof and merges and supersedes all prior discussions, agreements and understandings of any and every nature among them. 

  
 20 









 6.4 Upon the execution and delivery of this Agreement by the Subscriber, this Agreement
shall become a binding obligation of the Subscriber with respect to the purchase of Series A Stock as herein provided, subject, however, to the right hereby reserved by the Company to enter into the same agreements with other subscribers and to add
and/or delete other persons as subscribers. 
 6.5 NOTWITHSTANDING THE PLACE WHERE THIS AGREEMENT MAY BE EXECUTED BY ANY OF THE
PARTIES HERETO, THE PARTIES EXPRESSLY AGREE THAT ALL THE TERMS AND PROVISIONS HEREOF SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE SUBSTANTIVE AND PROCEDURAL LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO SUCH STATE’S PRINCIPLES OF
CONFLICTS OF LAW. IN THE EVENT THAT A JUDICIAL PROCEEDING IS NECESSARY, THE SOLE FORUM FOR RESOLVING DISPUTES ARISING OUT OF OR RELATING TO THIS AGREEMENT IS THE STATE AND FEDERAL COURTS SITTING IN THE BOROUGH OF MANHATTAN, COUNTY OF NEW YORK. THE
PARTIES HEREBY IRREVOCABLY CONSENT TO THE JURISDICTION OF SUCH COURTS AND AGREE TO SAID VENUE. 
 6.6 The holding of any
provision of this Agreement to be invalid or unenforceable by a court of competent jurisdiction shall not affect any other provision of this Agreement, which shall remain in full force and effect. If any provision of this Agreement shall be declared
by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced in whole or in part, such provision shall be interpreted so as to remain enforceable to the maximum extent permissible consistent with applicable law and the
remaining conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable to the extent they are valid, legal and enforceable, and no provisions shall be deemed dependent upon any other covenant or
provision unless so expressed herein. 
 6.7 It is agreed that a waiver by either party of a breach of any provision of this
Agreement shall not operate, or be construed, as a waiver of any subsequent breach by that same party. 
 6.8 The parties agree
to execute and deliver all such further documents, agreements and instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Agreement. 

6.9 This Agreement may be executed in two or more counterparts each of which shall be deemed an original, but all of which shall together
constitute one and the same instrument. 
 6.10 Nothing in this Agreement shall create or be deemed to create any rights in any
person or entity not a party to this Agreement, except (a) for the holders of Registrable Securities; (b) for the Placement Agents pursuant to Sections 1.6(a), 1.23 and 3.1 hereof, (c) for the indemnified parties (including without
limitation the Placement Agents and sub agents, if any) pursuant to Section 5.9 hereof; and (d) that the Placement Agents may rely upon the representations and acknowledgements of the Subscriber in Articles I and VII hereof and the
representations and warranties of the Company in Article II hereof. 
 Remainder of Page Intentionally Left Blank.


  
 21 










	VII.	CONFIDENTIAL INVESTOR QUESTIONNAIRE 

 7.1 ALL INVESTORS - The undersigned represents and warrants as indicated below by the undersigned’s mark: 

 

	A.	Individual investors: (Please mark one or more of the following statements) 


 

					
	1.	 	        	 	I certify that I am an accredited investor because I have had individual income (exclusive of any income earned by my spouse) of more than $200,000 in each of the most recent two
years and I reasonably expect to have an individual income in excess of $200,000 for the current year.
			
	2.	 	        	 	I certify that I am an accredited investor because I have had joint income with my spouse in excess of $300,000 in each of the most recent two years and reasonably expect to have
joint income with my spouse in excess of $300,000 for the current year.
			
	3.	 	        	 	I certify that I am an accredited investor because I have an individual net worth, or my spouse and I have a joint net worth, in excess of $1,000,000.
			
	4.	 	        	 	I am a director or executive officer of Coronado Biosciences, Inc.
	
	 B.      Partnerships, corporations, trusts or other entities: (Please mark one
of the following seven statements). The undersigned hereby certifies that it is an accredited investor because it is:

			
	1.	 	        	 	an employee benefit plan whose total assets exceed $5,000,000;
			
	2.	 	        	 	an employee benefit plan whose investments decisions are made by a plan fiduciary which is either a bank, savings and loan association or an insurance company (as defined in Section
3(a) of the Securities Act) or an investment adviser registered as such under the Investment Advisers Act of 1940;
			
	3.	 	        	 	a self-directed employee benefit plan, including an Individual Retirement Account, with investment decisions made solely by persons that are accredited investors;
			
	4.	 	        	 	an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, not formed for the specific purpose of acquiring the Shares, with total assets in
excess of $5,000,000;
			
	5.	 	        	 	a corporation, partnership, limited liability company, limited liability partnership, other entity or similar business trust, not formed for the specific purpose of acquiring the
Series A Stock, with total assets in excess of $5,000,000;
			
	6.	 	        	 	a trust, not formed for the specific purpose of acquiring the Series A Stock, with total assets exceeding $5,000,000, whose purchase is directed by a person who has such knowledge
and experience in financial and business matters that he is capable of evaluating the merits and risks of an investment in the Series A Stock; or
			
	7.	 	        	 	an entity (including a revocable grantor trust but other than a conventional trust) in which each of the equity owners qualifies as an accredited investor.


  
 22 









 7.2 EUROPEAN ECONOMIC AREA (“EEA”) INVESTORS - The undersigned further
represents and warrants as indicated below by the undersigned’s mark: 
  

	A.	Please mark one of the following statements: 

 either 

1.            The undersigned hereby certifies that it is a Qualified
Investor for the purposes of Directive 2003/71/EC because it is a person falling within Article 2.1(e)(i), (ii) or (iii) of such directive or a person authorized by a jurisdiction in the EEA to be considered as a qualified investor for the
purposes of such directive; 
 or 
 2.            The undersigned hereby certifies that it is not a Qualified Investor for the purposes of Directive 2003/71/EC. 

 

	B.	Please mark one of the following statements. 

 1.            The undersigned hereby certifies that it is acting on its own account and not for the account of or otherwise on behalf of
any person or persons; or 
 2.            The undersigned is
in the United Kingdom and is a Qualified Investor for the purposes of Directive 2003/71/EC and is acting as an agent in the circumstances contemplated in section 86(2) of the United Kingdom Financial Services and Markets Act 2000. 

 

	C.	Please mark the following statement: 

 1.            The undersigned hereby certifies that it has not received any recommendation from any Placement Agent nor any person acting
on their behalf in relation to the purchase of the Securities. 
  

	D.	Please mark one of the following statements: 

 1.            The undersigned hereby certifies that it is not in the United Kingdom. 

2.            The undersigned hereby certifies that it is a person
falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“FPO”). 

3.            The undersigned hereby certifies that it is a person
falling within Article 49(2)(a) to the (d) of the FPO. 
 7.3 ALL INVESTORS - The undersigned further represents and
warrants as indicated below by the undersigned’s mark: 
 FINRA AFFILIATION. 

Are you affiliated or associated with an FINRA member firm: 
 Yes                         No
             

  
 23 









 If Yes, please describe: 
  

 
  

 
  

 
  

	*	If subscriber is a Registered Representative with an FINRA member firm, have the following acknowledgment signed by the appropriate party: 


The undersigned FINRA member firm acknowledges receipt of the notice required by NASD Rule 3050. 

 

			
	  

	Name of FINRA Member Firm
		
	By:	 	  



			
		 	    Authorized Officer
		
	Date:	 	  


 7.4 ALL INVESTORS - Indicate manner in which title is to be held (circle one) 

 

	 	(a)	Individual Ownership 

  

	 	(b)	Community Property 

  

	 	(c)	Joint Tenant with Right of Survivorship (both parties must sign) 

  

	 	(d)	Partnership 

  

	 	(e)	Tenants in Common 

  

	 	(f)	Corporation 

  

	 	(g)	Limited Liability Company 

  

	 	(h)	Trust 

  

	 	(i)	Other 

 7.5 ALL INVESTORS
- Please answer each question. 
 SUITABILITY 
 (a) For an individual Subscriber, please describe your current employment, including the company by which you are employed and its principal business: 

 
  
  

 
  

 
  

 
 (b) For an individual Subscriber, please
describe any college or graduate degrees held by you: 
  
  

 
  
  

 

  
 24 









 (c) For all Subscribers, please list types of prior investments: 

 
  
  

 
  

 
 (d) For all Subscribers, please state whether
you have you participated in other private placements before: 
 YES
                            NO
             
 (e) If your answer to question 7.2(d) above was
“YES”, please indicate frequency of such prior participation in private placements of: 
  

							
	 	  	Public
Companies	  	Private
Companies	  	Public or Private
Biopharmaceutical Companies
	 Frequently
	  	                	  	                	  	                
	 Occasionally
	  	                	  	                	  	                
	 Never
	  	                	  	                	  	                

 (f) For individual Subscribers, do you expect your current level of income to significantly decrease in the foreseeable
future: 
 YES
                        NO              

(g) For trust, corporate, partnership and other institutional Subscribers, do you expect your total assets to significantly decrease in the foreseeable
future: 
 YES
                            NO
             
 (h) For all Subscribers, do you have any other investments or
contingent liabilities which you reasonably anticipate could cause you to need sudden cash requirements in excess of cash readily available to you: 
 YES                             NO
             
 (i) For all Subscribers, are you familiar with the risk
aspects and the non-liquidity of investments such as the securities for which you seek to subscribe? 
 YES
                            NO
             
 (j) For all Subscribers, do you understand that there is no
guarantee of financial return on this investment and that you run the risk of losing your entire investment? 
 YES
                            NO
             

  
 25 









 7.6 The undersigned is informed of the significance to the Company of the foregoing
representations and answers contained in the Confidential Investor Questionnaire contained in this Article VII and such answers have been provided under the assumption that the Company will rely on them. 

 

			
	Signature:	 	  

		
		 	  

		 	(If purchased jointly)
		
	Print Name:	 	  

		
		 	  

		 	(If purchased jointly)
		
	Date:	 	  



  
 26 









 AGGREGATE SUBSCRIPTION AMOUNT:
$                     
 NUMBER
OF SHARES (at $8.39 per share):                      
  

							
	  
	  		  	  
	  	
	Signature	  		  	Signature (if purchasing jointly)	  	
				
	  
	  		  	  
	  	
	Name Typed or Printed	  		  	Name Typed or Printed	  	
				
	  
	  		  	  
	  	
	Entity Name	  		  	Entity Name	  	
				
	  
	  		  	  
	  	
	Address	  		  	Address	  	
				
	  
	  		  	  
	  	
	City, State and Zip Code	  		  	City, State and Zip Code	  	
				
	  
	  		  	  
	  	
	Telephone-Business	  		  	Telephone-Business	  	
				
	  
	  		  	  
	  	
	Telephone-Residence	  		  	Telephone-Residence	  	
				
	  
	  		  	  
	  	
	Facsimile-Business	  		  	Facsimile-Business	  	
				
	  
	  		  	  
	  	
	Facsimile-Residence	  		  	Facsimile-Residence	  	
				
	  
	  		  	  
	  	
	Tax ID # or Social Security #	  		  	Tax ID # or Social Security #	  	
		  		  		  	
	Name in which securities should be issued:	  	  
	  	

 Dated:             , 2010 







 This Subscription Agreement is agreed to and accepted as of
            , 2010. 
  

			
	Coronado Biosciences, Inc.
		
	By:	 	  

	Name:	 	Raymond J. Tesi, M.D.
	Title:	 	President and Chief Executive Office









 CERTIFICATE OF SIGNATORY 

(To be completed if Securities are 
 being subscribed for by an entity) 
 I,
                    , am the
                     of
                     (the “Entity”). 
 I certify that I am empowered and duly authorized by the Entity to execute and carry out the terms of the Subscription Agreement and to purchase and hold the Securities, and certify further that the
Subscription Agreement has been duly and validly executed on behalf of the Entity and constitutes a legal and binding obligation of the Entity. 

IN WITNESS WHEREOF, I have set my hand this      day of
            ,          
  

	
	  

	(Signature)